Network-based approach to prediction and population-based validation of in silico drug repurposing

Nature Communications

Volumn 9, Issue 1, 2018, Pages

  Cheng, Feixiong ^a,b   Desai, Rishi J ^c   Handy, Diane E ^c   Wang, Ruisheng ^c   Schneeweiss, Sebastian ^c   Barabási, Albert László ^a,b,d,e   Loscalzo, Joseph ^c  

^a NORTHEASTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e CENTRAL EUROPEAN UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CYTOKINE; HYDROXYCHLOROQUINE;

CELL COMPONENT; CONFIDENCE INTERVAL; DATABASE; DISEASE; DRUG; MODEL VALIDATION; NETWORK ANALYSIS; PREDICTION; PROTEIN;

AORTIC ENDOTHELIAL CELL; ARTICLE; COMPUTER MODEL; CORONARY ARTERY DISEASE; DATA BASE; DRUG EFFECT; DRUG REPOSITIONING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; PHARMACOEPIDEMIOLOGY; PREDICTION; PROPENSITY SCORE; PROTEIN PROTEIN INTERACTION; COMPUTER SIMULATION; FACTUAL DATABASE; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN ANALYSIS; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

CARBAMAZEPINE; COMPUTER SIMULATION; CORONARY ARTERY DISEASE; DATABASES, FACTUAL; DRUG REPOSITIONING; HUMANS; HYDROXYCHLOROQUINE; PROGNOSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROTEIN INTERACTION MAPS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS;

EID: 85050009917     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-018-05116-5     Document Type: Article

References (90)

1. Mullard, A. 2016 FDA drug approvals. Nat. Rev. Drug Discov. 16, 73-76 (2017).
2. Shih, H. P., Zhang, X. &Aronov, A. M. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nat. Rev. Drug Discov. 17, 19-33 (2017).
3. Antman, E. M. &Loscalzo, J. Precision medicine in cardiology. Nat. Rev. Cardiol. 13, 591-602 (2016).
4. MacRae, C. A., Roden, D. M. &Loscalzo, J. The future of cardiovascular therapeutics. Circulation 133, 2610-2617 (2016).
5. Greene, J. A. &Loscalzo, J. Putting the patient back together-social medicine, network medicine, and the limits of reductionism. N. Engl. J. Med. 377, 2493-2499 (2017).
6. Menche, J. et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science 347, 1257601 (2015).
7. Yildirim, M. A., Goh, K. I., Cusick, M. E., Barabasi, A. L. &Vidal, M. Drugtarget network. Nat. Biotechnol. 25, 1119-1126 (2007).
8. Wang, R. S. &Loscalzo, J. Illuminating drug action by network integration of disease genes: a case study of myocardial infarction. Mol. Biosyst. 12, 1653-1666 (2016).
9. Dudley, J. T. et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 3, 96ra76 (2011).
10. Guney, E., Menche, J., Vidal, M. &Barabasi, A. L. Network-based in silico drug efficacy screening. Nat. Commun. 7, 10331 (2016).
11. Zhao, S. et al. Systems pharmacology of adverse event mitigation by drug combinations. Sci. Transl. Med. 5, 206ra140 (2013).
12. Himmelstein, D. S. et al. Systematic integration of biomedical knowledge prioritizes drugs for repurposing. eLife 6, e26726 (2017).
13. Schneeweiss, S. et al. Real world data in adaptive biomedical innovation: a framework for generating evidence fit for decision making. Clin. Pharmacol. Ther. 100, 633-646 (2016).
14. Schneeweiss, S. &Avorn, J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J. Clin. Epidemiol. 58, 323-337 (2005).
15. Schneeweiss, S. et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20, 512 (2009).
16. Brilliant, M. H. et al. Mining retrospective data for virtual prospective drug repurposing: L-DOPA and age-related macular degeneration. Am. J. Med. 129, 292-298 (2016).
17. Goh, K. I. et al. The human disease network. Proc. Natl Acad. Sci. USA 104, 8685-8690 (2007).
18. Ghiassian, S. D., Menche, J. &Barabasi, A. L. A DIseAse MOdule Detection (DIAMOnD) algorithm derived from a systematic analysis of connectivity patterns of disease proteins in the human interactome. PLoS Comput. Biol. 11, e1004120 (2015).
19. Rolland, T. et al. A proteome-scale map of the human interactome network. Cell 159, 1212-1226 (2014).
20. Wang, S. V. et al. Transparency and reproducibility of observational cohort studies using large healthcare databases. Clin. Pharmacol. Ther. 99, 325-332 (2016).
21. Schneeweiss, S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol. Drug. Saf. 19, 858-868 (2010).
22. Sharma, T. S. et al. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J. Am. Heart Assoc. 5, e002867 (2016).
23. Lamphier, M. et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol. Pharmacol. 85, 429-440 (2014).
24. Le, N. T. et al. Identification of activators of ERK5 transcriptional activity by high-throughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agents. J. Immunol. 193, 3803-3815 (2014).
25. Muller-Calleja, N., Manukyan, D., Canisius, A., Strand, D. &Lackner, K. J. Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase. Ann. Rheum. Dis. 76, 891-897 (2017).
26. Hwang, S. J. et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96, 4219-4225 (1997).
27. Tousoulis, D., Oikonomou, E., Economou, E. K., Crea, F. &Kaski, J. C. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur. Heart J. 37, 1723-1732 (2016).
28. Kaptoge, S. et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur. Heart J. 35, 578-589 (2014).
29. Herbrig, K. et al. Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells. Ann. Rheum. Dis. 65, 157-163 (2006).
30. Sandoo, A., Kitas, G. D., Carroll, D. &Veldhuijzen van Zanten, J. J. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Res. Ther. 14, R117 (2012).
31. Anderson, H. D., Rahmutula, D. &Gardner, D. G. Tumor necrosis factoralpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J. Biol. Chem. 279, 963-969 (2004).
32. Jaramillo, N. M. et al. Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response. Drug Metabol. Drug Interact. 29, 67-79 (2014).
33. Chen, P. C. et al. Carbamazepine as a novel small molecule corrector of trafficking-impaired ATP-sensitive potassium channels identified in congenital hyperinsulinism. J. Biol. Chem. 288, 20942-20954 (2013).
34. Beermann, B., Edhag, O. &Vallin, H. Advanced heart-block aggravated by carbamazepine. Br. Heart J. 37, 668-671 (1975).
35. Svalheim, S. et al. Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine. Acta Neurol. Scand. 122, 30-33 (2010).
36. Saffitz, J. E. Structural heart disease, SCN5A gene mutations, and Brugada syndrome: a complex menage a trois. Circulation 112, 3672-3674 (2005).
37. Yamagata, K. et al. Genotype-phenotype correlation of SCN5A mutation for the clinical and electrocardiographic characteristics of probands with Brugada syndrome: a Japanese multicenter registry. Circulation 135, 2255-2270 (2017).
38. Nichols, C. G., Singh, G. K. &Grange, D. K. KATP channels and cardiovascular disease: suddenly a syndrome. Circ. Res. 112, 1059-1072 (2013).
39. Lan, C. C. et al. A reduced risk of stroke with lithium exposure in bipolar disorder: a population-based retrospective cohort study. Bipolar Disord. 17, 705-714 (2015).
40. Patorno, E. et al. Lithium use in pregnancy and the risk of cardiac malformations. N. Engl. J. Med. 376, 2245-2254 (2017).
41. Rainsford, K. D., Parke, A. L., Clifford-Rashotte, M. &Kean, W. F. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23, 231-269 (2015).
42. Kuznik, A. et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 186, 4794-4804 (2011).
43. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-1695 (2005).
44. Shukla, A. M. et al. Impact of hydroxychloroquine on atherosclerosis and vascular stiffness in the presence of chronic kidney disease. PLoS ONE 10, e0139226 (2015).
45. Cendrowski, J., Maminska, A. &Miaczynska, M. Endocytic regulation of cytokine receptor signaling. Cytokine Growth Factor Rev. 32, 63-73 (2016).
46. Muller-Calleja, N., Manukyan, D., Canisius, A., Strand, D. &Lackner, K. J. Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase. Ann. Rheum. Dis. 76, 891-897 (2016).
47. Hartman, O., Kovanen, P. T., Lehtonen, J., Eklund, K. K. &Sinisalo, J. Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. Eur. Heart J. Cardiovasc. Pharmacother. 3, 92-97 (2017).
48. Olsen, N. J., Schleich, M. A. &Karp, D. R. Multifaceted effects of hydroxychloroquine in human disease. Semin. Arthritis Rheum. 43, 264-272 (2013).
49. West, S. L. et al. Completeness of prescription recording in outpatient medical records from a health maintenance organization. J. Clin. Epidemiol. 47, 165-171 (1994).
50. Sherman, R. E. et al. Real-world evidence-what is it and what can it tell us? N. Engl. J. Med. 375, 2293-2297 (2016).
51. Rual, J. F. et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 437, 1173-1178 (2005).
52. Cheng, F., Jia, P., Wang, Q. &Zhao, Z. Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. Oncotarget 5, 3697-3710 (2014).
53. Peri, S. et al. Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res. 32, D497-D501 (2004).
54. Newman, R. H. et al. Construction of human activity-based phosphorylation networks. Mol. Syst. Biol. 9, 655 (2013).
55. Hu, J. et al. PhosphoNetworks: a database for human phosphorylation networks. Bioinformatics 30, 141-142 (2014).
56. Hornbeck, P. V. et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512-D520 (2015).
57. Lu, C. T. et al. DbPTM 3.0: an informative resource for investigating substrate site specificity and functional association of protein post-translational modifications. Nucleic Acids Res. 41, D295-D305 (2013).
58. Dinkel, H. et al. Phospho.ELM: a database of phosphorylation sites-update 2011. Nucleic Acids Res. 39, D261-D267 (2011).
59. Chatr-Aryamontri, A. et al. The BioGRID interaction database: 2015 update. Nucleic Acids Res. 43, D470-D478 (2015).
60. Cowley, M. J. et al. PINA v2.0: mining interactome modules. Nucleic Acids Res. 40, D862-D865 (2012).
61. Licata, L. et al. MINT, the molecular interaction database: 2012 update. Nucleic Acids Res. 40, D857-D861 (2012).
62. Orchard, S. et al. The MIntAct project-IntAct as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res. 42, D358-D363 (2014).
63. Breuer, K. et al. InnateDB: systems biology of innate immunity and beyond-recent updates and continuing curation. Nucleic Acids Res. 41, D1228-D1233 (2013).
64. Meyer, M. J., Das, J., Wang, X. &Yu, H. INstruct: a database of high-quality 3D structurally resolved protein interactome networks. Bioinformatics 29, 1577-1579 (2013).
65. Fazekas, D. et al. SignaLink 2-A signaling pathway resource with multilayered regulatory networks. BMC Syst. Biol. 7, 7 (2013).
66. Coordinators, N. R. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 44, D7-D19 (2016).
67. Bodenreider, O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res. 32, D267-D270 (2004).
68. Amberger, J. S., Bocchini, C. A., Schiettecatte, F., Scott, A. F. &Hamosh, A. OMIM.org: Online Mendelian Inheritance in Man (OMIM(R)), an online catalog of human genes and genetic disorders. Nucleic Acids Res. 43, D789-D798 (2015).
69. Davis, A. P. et al. The comparative toxicogenomics database's 10th year anniversary: update 2015. Nucleic Acids Res. 43, D914-D920 (2015).
70. Yu, W., Gwinn, M., Clyne, M., Yesupriya, A. &Khoury, M. J. A navigator for human genome epidemiology. Nat. Genet. 40, 124-125 (2008).
71. Pinero, J. et al. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. Database 2015, bav028 (2015).
72. Landrum, M. J. et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42, D980-D985 (2014).
73. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 42, D1001-D1006 (2014).
74. Li, M. J. et al. GWASdb v2: an update database for human genetic variants identified by genome-wide association studies. Nucleic Acids Res. 44, D869-D876 (2016).
75. Denny, J. C. et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat. Biotechnol. 31, 1102-1110 (2013).
76. Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091-D1097 (2014).
77. Zhu, F. et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 40, D1128-D1136 (2012).
78. Hernandez-Boussard, T. et al. The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge. Nucleic Acids Res. 36, D913-D918 (2008).
79. Gaulton, A. et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-D1107 (2012).
80. Liu, T. Q., Lin, Y. M., Wen, X., Jorissen, R. N. &Gilson, M. K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 35, D198-D201 (2007).
81. Pawson, A. J. et al. The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res. 42, D1098-D1106 (2014).
82. Apweiler, R. et al. UniProt: the Universal Protein knowledgebase. Nucleic Acids Res. 32, D115-D119 (2004).
83. Ray, W. A. Evaluating medication effects outside of clinical trials: new-user designs. Am. J. Epidemiol. 158, 915-920 (2003).
84. Kiyota, Y. et al. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am. Heart J. 148, 99-104 (2004).
85. Hlatky, M. A. et al. Use of medicare data to identify coronary heart disease outcomes in the Women's health initiative. Circ. Cardiovasc. Qual. Outcomes 7, 157-162 (2014).
86. Birman-Deych, E. et al. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med. Care 43, 480-485 (2005).
87. Rosenbaum, P. R. &Rubin, D. B. The central role of the propensity score in observational studies for causal effects. Biometrika 70, 41-55 (1983).
88. Austin, P. C. Some Methods of Propensity-score matching had superior performance to others: results of an empirical investigation and monte carlo simulations. Biomet. J. 51, 171-184 (2009).
89. DerSimonian, R. &Laird, N. Meta-analysis in clinical trials. Control Clin. Trials 7, 177-188 (1986).
90. Kitsak, M. et al. Tissue specificity of human disease module. Sci. Rep. 6, 35241 (2016).